Comparison
Abbott Laboratories (Pakistan) Limited vs GlaxoSmithKline Pakistan Limited
GlaxoSmithKline Pakistan Limited (GLAXO) is worth Rs 99.4 bn at the latest close, 1.1 times the market value of Abbott Laboratories (Pakistan) Limited (ABOT) at Rs 91.9 bn. In their latest annual results ABOT reported revenue of Rs 75.4 bn (FY2025) and GLAXO Rs 65.9 bn (FY2025). ABOT trades at 10.7× earnings and GLAXO at 9.5×. Dividend yields: ABOT 4.3%, GLAXO 5.4%.
| Latest | ABOT FY2025 | GLAXO FY2025 |
|---|---|---|
| Price | Rs 938.50 | Rs 312.07 |
| Market value | Rs 91.9 bn | Rs 99.4 bn |
| P/E | 10.7× | 9.5× (stronger) |
| P/B | 2.86× (stronger) | 2.89× |
| Dividend yield | 4.3% | 5.4% (stronger) |
| Revenue (latest year) | Rs 75.4 bn | Rs 65.9 bn |
| Revenue growth, year on year | 10.6% (stronger) | 7.7% |
| Revenue growth, 5 years a year | 16.4% (stronger) | 13.4% |
| Profit (latest year) | Rs 8.0 bn | Rs 10.0 bn (stronger) |
| EPS (latest year) | Rs 81.37 | Rs 31.48 |
| Dividend per share | Rs 40.00 | Rs 17.00 |
| Net margin | 10.6% | 15.2% (stronger) |
| Return on equity | 28.8% | 32.4% (stronger) |
| Debt to equity | 1.5% | 1.1% (stronger) |
| Current ratio | 2.32× | 2.32× (stronger) |
| Dividend streak (years) | 2 | 2 |
Highlighted: the higher figure where higher is usually stronger (growth, margins, returns, yield) or the lower where lower is (P/E, P/B, debt). A highlight is a comparison, not a recommendation.
ABOT
Abbott Laboratories (Pakistan) Limited financial statements →
GLAXO
GlaxoSmithKline Pakistan Limited financial statements →
Related comparisons
Prices at the latest close; financial figures from each company's latest annual report. Information only, not investment advice.